We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Evotec Earns Milestone in Oncology Programme as Part of its Research Alliance with Boehringer Ingelheim


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Earns Milestone in Oncology Programme as Part of its Research Alliance with Boehringer Ingelheim"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Evotec AG has announced that it has achieved a milestone as part of its research alliance with Boehringer Ingelheim and will receive a payment of EUR 2.5 million. The milestone was achieved for the selection of a candidate compound for pre-development studies in an oncology programme.

Dr Werner Lanthaler, Chief Executive Officer of Evotec commented: “We are particularly pleased about achieving this milestone in the oncology programme, as the alliance was only expanded to this therapeutic area in late 2009. We are very proud of the high value we continue to bring to Boehringer Ingelheim’s research efforts and the ongoing fruitful relationship between the research teams from both companies.”

Advertisement